Latest Legal Proceedings Impact News

Page 1 of 1

Mayne Pharma Reports 6% Revenue Decline Amid Women’s Health Growth and DistributeRx Expansion

Mayne Pharma’s FY26 results reveal a 6% revenue dip and 33% EBITDA fall, offset by strong Women’s Health momentum and a major distribution capacity boost.

Victor Sage

31 July 2026

Browse the archive

Full archive

July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026 Dec 2025

Top